Incyte (INCY) Leerink Global Healthcare Conference 2026 summary

Strategic focus and business outlook

• Core business excluding Jakafi is projected to reach $3–4 billion in sales over five years, aiming to match Jakafi’s size by 2030, with key products including Opzelura, Niktimvo, Monjuvi, XR, and povorcitinib expected to drive growth.

• Pipeline investment is concentrated on seven assets in hematology, oncology, and immunology, with 14 clinical studies planned by 2026 and potential for 2–3x top-line sales growth.

• Business development remains a priority to supplement growth and extend the core franchise.

Jakafi performance and lifecycle management

• Jakafi maintains mid-single-digit growth through 2028, with XR formulation launching mid-2026 to preserve revenue post-exclusivity; conversion rates to XR are estimated at 15–30%.

• Jakafi’s pricing is managed for stability, with XR expected to be priced for parity to ensure formulary access and patient affordability.

• Jakafi remains the standard of care in myelofibrosis (MF), polycythemia vera (PV), and graft-versus-host disease (GVHD), with no major disruption expected from competitors in the near term.

INCA33989 and CALR-targeted innovation

• INCA33989, a CALR antibody, demonstrated first-line efficacy in second-line MF and ET settings, with superior molecular and clinical endpoints compared to current therapies.

• Phase III trials for INCA33989 in ET and MF will begin mid-to-late 2024, aiming to establish molecular-targeted therapies as the new standard of care in MPNs.

• INCA33989 shows potential for disease modification by eradicating mutated cells, improving anemia, and reducing bone marrow fibrosis.

• Dosing strategies are being refined to address differences in CALR mutation types, with pivotal trial designs and endpoints to be clarified by April.